-
Tytuł:
-
[New oral antidiabetic drugs].
-
Autorzy:
-
Müller-Wieland D; Medizinische Klinik I, Universitätsklinikum RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Deutschland. .
Schütt K; Medizinische Klinik I, Universitätsklinikum RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Deutschland.
Brandts J; Medizinische Klinik I, Universitätsklinikum RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Deutschland.
Marx N; Medizinische Klinik I, Universitätsklinikum RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Deutschland.
-
Transliterated Title:
-
Neue orale Antidiabetika.
-
Źródło:
-
Herz [Herz] 2020 Aug; Vol. 45 (5), pp. 493-503.
-
Typ publikacji:
-
Journal Article
-
Język:
-
German
-
Imprint Name(s):
-
Publication: Munchen : Urban Und Vogel
Original Publication: München, Urban & Schwarzenberg.
-
MeSH Terms:
-
Diabetes Mellitus, Type 2*/drug therapy
Dipeptidyl-Peptidase IV Inhibitors*
Hypoglycemic Agents*/therapeutic use
Sodium-Glucose Transporter 2 Inhibitors*
Glycated Hemoglobin ; Humans
-
Contributed Indexing:
-
Keywords: DPP‑4 inhibitors; Diabetes mellitus type 2; GLP‑1 receptor agonists; Heart failure; Sodium-glucose transporter 2 inhibitors
-
Substance Nomenclature:
-
0 (Dipeptidyl-Peptidase IV Inhibitors)
0 (Glycated Hemoglobin A)
0 (Hypoglycemic Agents)
0 (Sodium-Glucose Transporter 2 Inhibitors)
-
Entry Date(s):
-
Date Created: 20200701 Date Completed: 20200811 Latest Revision: 20221207
-
Update Code:
-
20240105
-
DOI:
-
10.1007/s00059-020-04946-8
-
PMID:
-
32601754
-
A paradigm change in the treatment of type 2 diabetes has recently emerged due to the introduction of new oral antidiabetic agents. Cardiovascular endpoint studies confirmed the safety of dipeptidyl peptidase 4 (DPP-4) inhibitors and a cardiovascular protective effect for glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose linked transporter 2 (SGLT-2) inhibitors. Furthermore, SGLT‑2 inhibitors reduce the risk for heart failure and have a renoprotective effect. These studies led to changes in clinical recommendations and guidelines. In patients with high or very high cardiorenal risk, SGLT‑2 inhibitors or GLP‑1 receptor agonists are recommended for risk protection independent of HbA1c values, with existing or high risk for chronic heart failure SGLT‑2 inhibitors are the preferred choice. Therefore, the choice of antidiabetic treatment strategy is no longer determined by the level of glycosylated hemoglobin (HbA1c) alone but particularly by the cardiorenal risk of the individual patient.
